CN109562062A - 含过氧金属酸盐的组合物，特别是预防性和治疗性药物组合物 - Google Patents

含过氧金属酸盐的组合物，特别是预防性和治疗性药物组合物 Download PDF

Info

Publication number
CN109562062A
CN109562062A CN201780029434.6A CN201780029434A CN109562062A CN 109562062 A CN109562062 A CN 109562062A CN 201780029434 A CN201780029434 A CN 201780029434A CN 109562062 A CN109562062 A CN 109562062A
Authority
CN
China
Prior art keywords
mixture
solution
composition
salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780029434.6A
Other languages
English (en)
Chinese (zh)
Inventor
雷米·威尔莫特
弗里德里克·洛伦佐
丹尼斯·奥利维尔·克雷蒂安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxsimo Technology Co Ltd
Original Assignee
Oxsimo Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxsimo Technology Co Ltd filed Critical Oxsimo Technology Co Ltd
Publication of CN109562062A publication Critical patent/CN109562062A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780029434.6A 2016-03-29 2017-03-29 含过氧金属酸盐的组合物，特别是预防性和治疗性药物组合物 Pending CN109562062A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1652697 2016-03-29
FR1652697A FR3049465B1 (fr) 2016-03-29 2016-03-29 Composition pharmaceutique preventive et curative a base de peroxometallate
PCT/IB2017/051797 WO2017168344A1 (fr) 2016-03-29 2017-03-29 Composition, notamment composition pharmaceutique préventive et curative, à base de peroxométallate

Publications (1)

Publication Number Publication Date
CN109562062A true CN109562062A (zh) 2019-04-02

Family

ID=56119576

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029434.6A Pending CN109562062A (zh) 2016-03-29 2017-03-29 含过氧金属酸盐的组合物，特别是预防性和治疗性药物组合物

Country Status (22)

Country Link
US (3) US10857179B2 (pt)
EP (1) EP3435979B1 (pt)
KR (1) KR102345412B1 (pt)
CN (1) CN109562062A (pt)
AU (1) AU2017243946B2 (pt)
BR (1) BR112018069814A2 (pt)
CA (1) CA3019739A1 (pt)
CL (1) CL2018002717A1 (pt)
CO (1) CO2018011344A2 (pt)
EA (1) EA038115B1 (pt)
FR (1) FR3049465B1 (pt)
IL (1) IL261982B2 (pt)
MA (1) MA44950B1 (pt)
MD (1) MD20190018A2 (pt)
MY (1) MY197527A (pt)
PE (1) PE20190259A1 (pt)
PH (1) PH12018502091A1 (pt)
SA (1) SA518400119B1 (pt)
SG (1) SG11201808651WA (pt)
TN (1) TN2018000332A1 (pt)
WO (1) WO2017168344A1 (pt)
ZA (2) ZA201806489B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
FR3049465B1 (fr) * 2016-03-29 2018-04-27 Oxymo Technologies Inc. Composition pharmaceutique preventive et curative a base de peroxometallate
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
FR3110396B1 (fr) 2020-05-20 2023-03-17 M G B Pharma Composition comprenant un composé ascorbo-camphorate métallique pour son utilisation dans le traitement des infections causées par herpèsvirus
WO2021262749A1 (en) * 2020-06-26 2021-12-30 Research Cancer Institute Of America Compositions and methods for preventing and/or treating viral infection
CN115246656B (zh) * 2022-01-12 2023-07-25 青岛大学 一种氧化钼/铁纳米材料的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059255A1 (en) * 2005-02-25 2007-03-15 Tichy Daryl J Methods and compositions for treating disease or injury
US20110123642A1 (en) * 2008-06-26 2011-05-26 Remi Wilmotte H2o2-based aqueous biocidal composition, method of manufacture and use
CN105408257A (zh) * 2013-04-25 2016-03-16 丝润有限责任公司 用于治疗氧化应激的螯合纳米铈氧化物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629191B2 (ja) 1984-09-04 1994-04-20 株式会社ポリトロニクス 抗腫瘍剤、抗ウィルス剤
JP2707252B2 (ja) 1987-08-03 1998-01-28 利博 山瀬 抗ウィルス剤
JP3121859B2 (ja) 1991-05-31 2001-01-09 利博 山瀬 抗ウイルス剤
JP4420997B2 (ja) 1999-02-08 2010-02-24 利博 山瀬 抗ウィルス剤
FR2792500B1 (fr) 1999-04-23 2004-05-21 Internat Redox Dev Composition aqueuse, notamment sous forme de gel, a base de ho2f , acides et ions metalliques, procede de preparation notamment quand lesdits ions sont ag2+ et utilisation dans le domaine de la desinfection et/ou du traitement de surface
FR2858086A1 (fr) * 2003-07-23 2005-01-28 France Telecom Procede d'estimation de la pertinence d'un document par rapport a un concept
FR3049465B1 (fr) * 2016-03-29 2018-04-27 Oxymo Technologies Inc. Composition pharmaceutique preventive et curative a base de peroxometallate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059255A1 (en) * 2005-02-25 2007-03-15 Tichy Daryl J Methods and compositions for treating disease or injury
US20110123642A1 (en) * 2008-06-26 2011-05-26 Remi Wilmotte H2o2-based aqueous biocidal composition, method of manufacture and use
CN105408257A (zh) * 2013-04-25 2016-03-16 丝润有限责任公司 用于治疗氧化应激的螯合纳米铈氧化物

Also Published As

Publication number Publication date
SG11201808651WA (en) 2018-11-29
US20230102115A1 (en) 2023-03-30
MY197527A (en) 2023-06-20
AU2017243946A1 (en) 2018-10-18
KR20190015208A (ko) 2019-02-13
EP3435979B1 (fr) 2023-06-14
CA3019739A1 (fr) 2017-10-05
WO2017168344A1 (fr) 2017-10-05
US11944639B2 (en) 2024-04-02
TN2018000332A1 (fr) 2020-01-16
ZA201806489B (en) 2019-08-28
EA201891941A1 (ru) 2019-04-30
MA44950B1 (fr) 2020-06-30
IL261982B (en) 2022-11-01
JP2019510773A (ja) 2019-04-18
FR3049465A1 (fr) 2017-10-06
PE20190259A1 (es) 2019-02-25
SA518400119B1 (ar) 2022-09-01
AU2017243946B2 (en) 2022-09-08
MD20190018A2 (ro) 2019-08-31
IL261982B2 (en) 2023-03-01
KR102345412B1 (ko) 2021-12-29
CL2018002717A1 (es) 2019-02-22
EP3435979C0 (fr) 2023-06-14
US20190125791A1 (en) 2019-05-02
EA038115B1 (ru) 2021-07-08
PH12018502091A1 (en) 2019-07-29
FR3049465B1 (fr) 2018-04-27
IL261982A (en) 2018-10-31
CO2018011344A2 (es) 2019-02-08
US20210030788A1 (en) 2021-02-04
MA44950A1 (fr) 2019-11-29
BR112018069814A2 (pt) 2019-01-29
US10857179B2 (en) 2020-12-08
ZA201902008B (en) 2021-01-27
EP3435979A1 (fr) 2019-02-06

Similar Documents

Publication Publication Date Title
CN109562062A (zh) 含过氧金属酸盐的组合物，特别是预防性和治疗性药物组合物
Eelen et al. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis
KR101846596B1 (ko) Ｃ형 간염 바이러스 억제제의 조합
JP5827962B2 (ja) Ｃｄｃ７キナーゼ阻害剤およびその使用
US20040019031A1 (en) Oxidant scavengers
ES2339683T3 (es) Diagnostico y tratamiento de canceres de celulas mieloides y linfoides.
CN106458957A (zh) 新型细胞可渗透琥珀酸化合物
EP3271333B1 (en) Usp7 inhibitor compounds and methods of use
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
WO2008036294A2 (en) Nos inhibitors for treatment of motor deficit disorders
JP2022533697A (ja) Ｇａｐｄｈを阻害する方法及び組成物
KR20160088886A (ko) 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 ｄ3 수용체 길항제로서의 크로모네 유도체
Eriksen et al. Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes
WO2009126335A2 (en) Ant2 inhibitor compounds and methods of use thereof
US20210346474A1 (en) Maspin, maspin derivatives, and maspin mimetics for reducing ros, inflammation, and skin aging
Chen et al. Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands
Sun et al. Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia
US11723907B2 (en) Anti-aging compounds
JP4791975B2 (ja) サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用
Sadek et al. N3, N7-diaminophenothiazinium derivatives as antagonists of α7-nicotinic acetylcholine receptors expressed in Xenopus oocytes
KR101943706B1 (ko) 유비퀴틴 활성 저해용 조성물
US11970490B2 (en) Stable heavy isotopes in amide functional groups and uses thereof
KR102597711B1 (ko) Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
JP7516006B2 (ja) 予防的及び治癒的ペルオキソメタレートベースの組成物、特に医薬組成物
Rogers et al. Putative gamma secretase modulators lower Aβ42 in multiple in vitro and in vivo models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination